Posted by Michael Wonder on 14 May 2022
Bridgebio Pharma sells rare pediatric disease priority review voucher for $110 million
13 May 2022 - Entered into a definitive agreement to sell the rare paediatric disease priority review voucher it obtained in February 2021 for $110 million.
BridgeBio Pharma announced today that it has entered into a definitive agreement with an undisclosed purchaser to sell its priority review voucher for $110 million.
